Patents by Inventor Terry L. Melim
Terry L. Melim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11344621Abstract: The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental.Type: GrantFiled: August 27, 2018Date of Patent: May 31, 2022Assignee: Abbvie, Inc.Inventors: Chengbin Wu, Richard W. Dixon, Jonathan P. Belk, Hua Ying, Maria A. Argiriadi, Carolyn A. Cuff, Paul R. Hinton, Shankar Kumar, Terry L. Melim, Yan Chen
-
Publication number: 20190008966Abstract: The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental.Type: ApplicationFiled: August 27, 2018Publication date: January 10, 2019Applicant: AbbVie Inc.Inventors: Chengbin Wu, Richard W. Dixon, Jonathan P. Belk, Hua Ying, Maria A. Argiriadi, Carolyn A. Cuff, Paul R. Hinton, Shankar Kumar, Terry L. Melim, Yan Chen
-
Patent number: 10086076Abstract: The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental.Type: GrantFiled: March 13, 2017Date of Patent: October 2, 2018Assignee: AbbVie Inc.Inventors: Chengbin Wu, Richard W. Dixon, Jonathan P. Belk, Hua Ying, Maria A. Argiriadi, Carolyn A. Cuff, Paul R. Hinton, Shankar Kumar, Terry L. Melim, Yan Chen
-
Publication number: 20170340737Abstract: The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental.Type: ApplicationFiled: March 13, 2017Publication date: November 30, 2017Inventors: Chengbin WU, Richard W. DIXON, Jonathan P. BELK, Hua YING, Maria A. ARGIRIADI, Carolyn A. CUFF, Paul R. HINTON, Shankar KUMAR, Terry L. MELIM, Yan CHEN
-
Patent number: 9592293Abstract: The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental.Type: GrantFiled: December 9, 2013Date of Patent: March 14, 2017Assignee: AbbVie Inc.Inventors: Chengbin Wu, Richard W. Dixon, Jonathan P. Belk, Maria A. Argiriadi, Hua Ying, Carolyn A. Cuff, Terry L. Melim, Shankar Kumar, Paul R. Hinton, Yan Chen
-
Publication number: 20140099313Abstract: The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental.Type: ApplicationFiled: December 9, 2013Publication date: April 10, 2014Applicant: ABBVIE INC.Inventors: Chengbin WU, Richard W. DIXON, Jonathan P. BELK, Maria A. ARGIRIADI, Hua YING, Carolyn A. CUFF, Terry L. MELIM, Shankar KUMAR, Paul R. HINTON, Yan CHEN
-
Patent number: 8604177Abstract: The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental.Type: GrantFiled: March 8, 2011Date of Patent: December 10, 2013Assignee: AbbVie Inc.Inventors: Chengbin Wu, Richard W. Dixon, Jonathan P. Belk, Maria A. Argiriadi, Hua Ying, Carolyn A. Cuff, Terry L. Melim, Shankar Kumar, Paul R. Hinton, Yan Chen
-
Publication number: 20110165066Abstract: The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental.Type: ApplicationFiled: March 8, 2011Publication date: July 7, 2011Inventors: Chengbin Wu, Richard W. Dixon, Jonathan P. Belk, Maria A. Argiriadi, Hua Ying, Carolyn A. Cuff, Terry L. Melim, Shankar Kumar, Paul R. Hinton, Yan Chen
-
Patent number: 7915388Abstract: The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental.Type: GrantFiled: September 7, 2007Date of Patent: March 29, 2011Assignee: Abbott LaboratoriesInventors: Chengbin Wu, Richard W. Dixon, Jonathan P. Belk, Maria A. Argiriadi, Hua Ying, Carolyn A. Cuff, Terry L. Melim, Shankar Kumar, Paul R. Hinton, Yan Chen
-
Publication number: 20080171014Abstract: The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental.Type: ApplicationFiled: September 7, 2007Publication date: July 17, 2008Inventors: Chengbin Wu, Richard W. Dixon, Jonathan P. Belk, Maria A. Argiriadi, Hua Ying, Carolyn A. Cuff, Terry L. Melim, Shankar Kumar, Paul R. Hinton, Yan Chen